UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1794) 1794
science & technology (1561) 1561
life sciences & biomedicine (1512) 1512
male (1173) 1173
female (1057) 1057
benzoates - therapeutic use (982) 982
benzoates - adverse effects (879) 879
adult (721) 721
middle aged (690) 690
animals (515) 515
benzoates - administration & dosage (478) 478
aged (476) 476
benzoates - pharmacology (436) 436
pharmacology & pharmacy (340) 340
treatment outcome (335) 335
benzimidazoles - therapeutic use (319) 319
hematology (293) 293
hypertension - drug therapy (274) 274
adolescent (269) 269
telmisartan (250) 250
abridged index medicus (236) 236
triazoles - therapeutic use (228) 228
child (215) 215
iron chelating agents - therapeutic use (214) 214
benzimidazoles - adverse effects (194) 194
double-blind method (192) 192
pyrazoles - therapeutic use (189) 189
blood pressure - drug effects (186) 186
hydrazines - therapeutic use (184) 184
angiotensin ii type 1 receptor blockers - therapeutic use (182) 182
drug therapy, combination (182) 182
hypertension (179) 179
cardiovascular system & cardiology (175) 175
triazoles - adverse effects (174) 174
iron overload - drug therapy (169) 169
deferasirox (167) 167
rats (167) 167
young adult (165) 165
iron chelating agents - adverse effects (161) 161
benzimidazoles - administration & dosage (160) 160
drug therapy (150) 150
time factors (148) 148
antihypertensive agents - therapeutic use (146) 146
analysis (145) 145
dose-response relationship, drug (143) 143
medicine & public health (140) 140
benzimidazoles - pharmacology (134) 134
child, preschool (133) 133
benzoates (131) 131
mice (131) 131
angiotensin-converting enzyme inhibitors - therapeutic use (130) 130
oncology (130) 130
care and treatment (129) 129
benzoates - pharmacokinetics (128) 128
pyrazoles - adverse effects (128) 128
hydrazines - adverse effects (127) 127
receptors, thrombopoietin - agonists (127) 127
aged, 80 and over (126) 126
prospective studies (124) 124
purpura, thrombocytopenic, idiopathic - drug therapy (124) 124
administration, oral (122) 122
general & internal medicine (120) 120
research (119) 119
peripheral vascular disease (118) 118
sodium benzoate (118) 118
medicine, general & internal (117) 117
triazoles - administration & dosage (114) 114
eltrombopag (113) 113
benzoic acid (110) 110
health aspects (110) 110
iron overload - etiology (110) 110
drug combinations (108) 108
iron chelating agents - administration & dosage (107) 107
antihypertensive agents - adverse effects (105) 105
risk factors (103) 103
internal medicine (102) 102
thrombocytopenia (102) 102
angiotensin-converting enzyme inhibitors - adverse effects (97) 97
iron overload (95) 95
toxicology (94) 94
angiotensin ii type 1 receptor blockers - adverse effects (93) 93
antihypertensive agents - administration & dosage (87) 87
pediatrics (87) 87
clinical trials (85) 85
clinical trials as topic (85) 85
dermatology (85) 85
hypertension - physiopathology (85) 85
platelet count (85) 85
pyrazoles - administration & dosage (85) 85
benzoates - chemistry (84) 84
ferritins - blood (84) 84
receptors, fc - therapeutic use (84) 84
hydrazines - administration & dosage (83) 83
transfusion reaction (82) 82
randomized controlled trials as topic (81) 81
blood pressure (80) 80
retrospective studies (80) 80
thrombopoietin - therapeutic use (78) 78
chronic disease (76) 76
angiotensin ii type 1 receptor blockers - pharmacology (75) 75
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2155) 2155
German (68) 68
French (39) 39
Japanese (38) 38
Spanish (17) 17
Russian (15) 15
Italian (7) 7
Chinese (4) 4
Polish (4) 4
Swedish (4) 4
Dutch (3) 3
Norwegian (3) 3
Danish (2) 2
Hungarian (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 09/2008, Volume 359, Issue 12, pp. 1225 - 1237
In a multicenter trial, 20,332 patients who had recently had an ischemic stroke were randomly assigned to receive either telmisartan or placebo. All patients... 
MORTALITY | HIGH-RISK PATIENTS | DESIGN | RAMIPRIL | RATIONALE | DOUBLE-BLIND | VASCULAR EVENTS | COMBINATION | UMCG Approved | BLOOD-PRESSURE | RANDOMIZED TRIAL | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Secondary Prevention | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Treatment Failure | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Heart Failure - epidemiology | Benzimidazoles - therapeutic use | Stroke - prevention & control | Kaplan-Meier Estimate | Stroke - drug therapy | Diabetes Mellitus - epidemiology | Creatinine - blood | Potassium - blood | Aged | Myocardial Infarction - prevention & control | Stroke (Disease) | Prevention | Usage | Health aspects | Telmisartan | Medical research | Stroke | Blood pressure | Index Medicus | Abridged Index Medicus | Blood Pressure | Creatinine | Recurrence | Benzimidazoles | Cardiovascular Diseases | Benzoates | Diabetes Mellitus | Geriatry and gerontology | Life Sciences | Human health and pathology | Myocardial Infarction | Angiotensin-Converting Enzyme Inhibitors | Heart Failure | Potassium | Cardiology and cardiovascular system | Original | Benzimidazoles/adverse effects/therapeutic use | Diabetes Mellitus/epidemiology | Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use | Recurrence/prevention & control | Stroke/drug therapy/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Creatinine/blood | Potassium/blood | Blood Pressure/drug effects | Cardiovascular Diseases/epidemiology/mortality/prevention & control | Benzoates/adverse effects/therapeutic use | Myocardial Infarction/epidemiology/prevention & control | Kaplan-Meiers Estimate | MEDICAL AND HEALTH SCIENCES | Heart Failure/epidemiology/prevention & control
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
.... We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
PloS one, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, pp. e0198184 - e0198184
Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and tolerability of the... 
Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9644, pp. 1174 - 1183
Journal Article
Obesity (Silver Spring, Md.), ISSN 1930-7381, 05/2013, Volume 21, Issue 5, pp. 985 - 992
.... Preclinical and clinical data suggest that appetite suppression is an important mechanism by which tesofensine exerts its robust weight reducing effect... 
Endocrinology & Metabolism | Life Sciences & Biomedicine | Nutrition & Dietetics | Science & Technology | Antihypertensive Agents - pharmacology | Appetite Depressants - adverse effects | Benzoates - therapeutic use | Metoprolol - pharmacology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Sympathomimetics - pharmacology | Anti-Obesity Agents - adverse effects | Male | Appetite Depressants - therapeutic use | Angiotensin II Type 1 Receptor Blockers - pharmacology | Anti-Obesity Agents - therapeutic use | Dose-Response Relationship, Drug | Heart Rate - drug effects | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Blood Pressure - drug effects | Benzimidazoles - therapeutic use | Sympathomimetics - adverse effects | Sympathomimetics - therapeutic use | Cardiovascular Diseases - etiology | Appetite Depressants - pharmacology | Appetite - drug effects | Metoprolol - therapeutic use | Energy Intake - drug effects | Antihypertensive Agents - therapeutic use | Rats, Sprague-Dawley | Feeding Behavior - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Obesity - prevention & control | Benzoates - pharmacology | Benzimidazoles - pharmacology | Anti-Obesity Agents - pharmacology | Obesity | Automation | Statistical analysis | Dopamine | Nuclear magnetic resonance--NMR | Telemetry | Abdomen | Heart rate | Weight control | Rodents | Monitoring systems | Software | Drug dosages | Food | Index Medicus
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 10/2011, Volume 31, Issue 10, pp. 2223 - 2231
Journal Article
American journal of hematology, ISSN 0361-8609, 11/2013, Volume 88, Issue 11, pp. 932 - 938
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
.... Outcomes were the same with telmisartan and ramipril, and there were more adverse events with combination therapy... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article